The Effect of MST 1 Inhibition through Hippo Pathway on Diabetes Mellitus (DM) Induced Osteoporosis
Downloads
Osteoporosis is a chronic metabolic disorder of the musculoskeletal system associated with reduced bone strength. One of the causes of secondary osteoporosis is diabetes mellitus (DM). The prevalence of both disorders keeps increasing with time. Therefore, this review is conducted to find a possible solution to prevent DM-induced osteoporosis. Diabetes mellitus mainly affects the bone through glucose uptake during the bone remodeling process. Glucose uptake through GLUT 1 is regulated by MST 1, which is an upstream kinase of the Hippo signaling pathway. MST 1 is responsible for regulating cell growth, proliferation, and apoptosis. In the bone remodeling process, MST 1 plays a role by regulating actin ring structures and the integrin signaling pathway. Moreover, DM is also associated with increased oxidative stress. Increased oxidative stress will activate Hippo signaling pathway. This will trigger cellular apoptosis as the Hippo signaling pathway plays a role mainly as a tumor suppressor. Increased cellular apoptosis will cause an imbalance in the bone remodeling process, disrupting bone quality. Inhibition of MST 1 through the Hippo signaling pathway will increase cell growth and reduce cellular apoptosis. Increased cell growth might increase osteogenesis during the bone remodeling process, thus resulting in better bone quality in DM-induced osteoporosis.
Sözen T, Özışık L, Başaran NÇ. An Overview and Management of Osteoporosis. Eur J Rheumatol 2017; 4: 46–56.
Kesehatan K. Infodatin Osteoporosis. Jakarta, https://pusdatin.kemkes.go.id/article/view/16010400003/data-dan-kondisi-penyakit-osteoporosis-di-indonesia.html (2015).
Miazgowski T, Kleerekoper M, Felsenberg D, et al. Secondary Osteoporosis: Endocrine and Metabolic Causes of Bone Mass Deterioration. J Osteoporos 2012; 2012: 907214.
Khan TS, Fraser L-A. Type 1 Diabetes and Osteoporosis: from Molecular Pathways to Bone Phenotype. J Osteoporos 2015; 2015: 174186.
World Health Organization. Diabeter [Internet], https://www.who.int/news-room/fact/detail/diabetes. (2018).
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41: S13–S27.
Wang T, Cai L, Wang Y, et al. The Protective Effects of Silibinin in The Treatment of Streptozotocin-Induced Diabetic Osteoporosis in Rats. Biomed Pharmacother 2017; 89: 681–688.
Li W, Deng Y, Feng B, et al. Mst1/2 Kinases Modulate Glucose Uptake for Osteoblast Differentiation and Bone Formation. J bone Miner Res Off J Am Soc Bone Miner Res 2018; 33: 1183–1195.
Meng Z, Moroishi T, Guan K-L. Mechanisms of Hippo Pathway Regulation. Genes Dev 2016; 30: 1–17.
Xu F, Wang Y-L, Chang J-J, et al. Mammalian Sterile 20-Like Kinase 1/2 Inhibits The Wnt/Β-Catenin Signalling Pathway by Directly Binding Casein Kinase 1ε. Biochem J 2014; 458: 159–169.
Triastuti E, Nugroho AB, Zi M, et al. Pharmacological Inhibition of Hippo Pathway, with The Novel Kinase Inhibitor XMU-MP-1, Protects The Heart Against Adverse Effects During Pressure Overload. Br J Pharmacol 2019; 176: 3956–3971.
Ardestani A, Paroni F, Azizi Z, et al. MST1 is A Key Regulator of Beta Cell Apoptosis and Dysfunction in Diabetes. Nat Med 2014; 20: 385–397.
Clarke B. Normal Bone Anatomy and Physiology. Clin J Am Soc Nephrol 2008; 3 Suppl 3: S131-9.
Crowder CM, Dominguez VM. Bone: Histological Analysis. In: Smith C (ed) Encyclopedia of Global Archaeology. New York, NY: Springer New York, pp. 978–985.
Lerner UH. Osteoblasts, Osteoclasts, and Osteocytes: Unveiling Their Intimate-Associated Responses to Applied Orthodontic Forces. Semin Orthod 2012; 18: 237–248.
Florencio-Silva R, Sasso GR da S, Sasso-Cerri E, et al. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed Res Int 2015; 2015: 421746.
Zhang K, Barragan-Adjemian C, Ye L, et al. E11/gp38 Selective Expression in Osteocytes: Regulation by Mechanical Strain and Role in Dendrite Elongation. Mol Cell Biol 2006; 26: 4539–4552.
Marc J. Bone Remodelling in Diabetes Mellitus. EJIFCC 2002; 13: 221–226.
Rosen CJ. The Epidemiology and Pathogenesis of Osteoporosis. In: Feingold KR, Anawalt B, Boyce A, et al. (eds). South Dartmouth (MA), 2000.
Niedźwiedzki T, Filipowska J. Bone Remodeling in The Context of Cellular and Systemic Regulation: The Role of Osteocytes and The Nervous System. J Mol Endocrinol 2015; 55: R23-36.
Bono CM, Einhorn TA. Overview of Osteoporosis: Pathophysiology and Determinants of Bone Strength. Eur spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 2003; 12 Suppl 2: S90-6.
Marcu F, Bogdan F, Muţiu G, et al. The Histopathological Study of Osteoporosis. Rom J Morphol Embryol = Rev Roum Morphol Embryol 2011; 52: 321–325.
Gödri DA, Neica L. Histological Criteria in Osteoporosis. 2010.
World Health Organization. Classification of Diabetes Mellitus, https://www.who.int/publications/i/item/classification-of-diabetes-mellitus (2018).
Organization WH. Classification of Diabetes Mellitus. Geneva PP - Geneva: World Health Organization, https://apps.who.int/iris/handle/10665/325182.
Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes 2017; 66: 241–255.
Damasceno DC, Netto AO, Iessi IL, et al. Streptozotocin-Induced Diabetes Models: Pathophysiological Mechanisms and Fetal Outcomes. Biomed Res Int 2014; 2014: 819065.
Guthrie RA, Guthrie DW. Pathophysiology of Diabetes Mellitus. Crit Care Nurs Q 2004; 27: 113–125.
Lello S, Capozzi A SG. Osteoporosis and Sarcopenia. 2019; 122.
Shahi M, Peymani A, Sahmani M. Regulation of Bone Metabolism. Reports Biochem Mol Biol 2017; 5: 73–82.
Karner CM, Long F. Glucose Metabolism in Bone. Bone 2018; 115: 2–7.
Kanazawa I, Sugimoto T. Diabetes Mellitus-Induced Bone Fragility. Intern Med 2018; 57: 2773–2785.
Cipriani C, Colangelo L, Santori R, et al. The Interplay Between Bone and Glucose Metabolism. Front Endocrinol (Lausanne) 2020; 11: 122.
Yu F-X, Guan K-L. The Hippo pathway: Regulators and Regulations. Genes Dev 2013; 27: 355–371.
Kim W, Khan SK, Gvozdenovic-Jeremic J, et al. Hippo Signaling Interactions with Wnt/Β-Catenin and Notch Signaling Repress Liver Tumorigenesis. J Clin Invest 2017; 127: 137–152.
Pombo CM, Iglesias C, Sartages M, et al. MST Kinases and Metabolism. Endocrinology 2019; 160: 1111–1118.
Galan JA, Avruch J. MST1/MST2 Protein Kinases: Regulation and Physiologic Roles. Biochemistry 2016; 55: 5507–5519.
Huijbregts PA. Osteoporosis: Epidemiology, Histology, Bone Remodeling, and Classification. J Man Manip Ther 2001; 9: 134–142.
Fan F, He Z, Kong L-L, et al. Pharmacological Targeting of Kinases MST1 and MST2 Augments Tissue Repair and Regeneration. Sci Transl Med 2016; 8: 352ra108.
Zhang T, Zhang Q, Wu S, et al. Mst1 Inhibition As A Cellular Mediator: Prevention of Anoikis in mBMSCs Through Activating ITGα5β1/FAK Signaling Pathway. 2021. Epub ahead of print 16 October 2021. DOI: 10.21203/rs.3.rs-977461/v1.
Liu X-F, Han Q, Yang M, et al. MST1 Inhibits Cell Proliferation and Invasion of Non-Small-Cell Lung Cancer by Regulating YAP Phosphorylation and Hippo Pathway. Int J Clin Exp Pathol 2018; 11: 2613–2620.
Odashima M, Usui S, Takagi H, et al. Inhibition of Endogenous Mst1 Prevents Apoptosis and Cardiac Dysfunction Without Affecting Cardiac Hypertrophy After Myocardial Infarction. Circ Res 2007; 100: 1344–1352.
Mitchell E, Mellor CEL, Purba TS. XMU-MP-1 Induces Growth Arrest in A Model Human Mini-Organ and Antagonises Cell Cycle-Dependent Paclitaxel Cytotoxicity. Cell Div 2020; 15: 11.
Neininger AC, Dai X, Liu Q, et al. The Hippo Pathway Regulates Density-Dependent Proliferation of Ipsc-Derived Cardiac Myocytes. Sci Rep 2021; 11: 17759.
Copyright (c) 2022 Indonesian Andrology and Biomedical Journal
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
